A unique consortium

The OPALE Carnot Institute is a consortium of 27 entities representing most of France's academic expertise in the research and development of therapeutic and diagnostic solutions for leukemia and related diseases. With no international equivalent, it offers healthcare companies a unique and comprehensive range of services to accelerate innovation and enhance its valorization across the entire R&D value chain.

Discover our entities

475
leukemia experts

OPALE's governance is assured by top-level research professionals, including many national and international scientific opinion leaders, as well as experienced professionals from R&D operations and their support functions (management, legal, business development, communications, etc.). Collectively, the entities comprising OPALE bring together nearly 475* leukemia experts, from basic research to clinical registration studies and real-life patient follow-up.
* Does not include contributing hospitals' research and innovation department support staff, nor the central services of OPALE entities' supervisory bodies.

Public-private partnerships at the core of research

OPALE aims to foster research partnerships between its entities and socio-economic players, including healthcare companies, to address their needs. The institute's ambition is to enable, within a decade, novel curative treatments, less detrimental, outpatient-compatible, and financially viable for all patients suffering from leukemia and related diseases. To achieve this, OPALE is investing in the professionalization of its research partnerships, to ensure a level of quality and efficacy in line with the requirements of the Carnot label and the expectations of industry.

Science that supports innovation

Every year, experts from the OPALE consortium publish around 350 papers in leading refereed journals, and make numerous presentations at international hematology congresses and events specializing in leukemia and related diseases. Many of these research projects have generated patents, databases, biological and image collections, which can lead to medical and industrial commercialization through licensing. On the basis of this first-rate scientific foundation, the OPALE Carnot Institute has also defined priority areas of work to accelerate innovation in partnership with socio-economic players.

See our strategic priorities